Imidazole propionate and fibrosis in cardiometabolic diseases

ERC (European Research Council)HORIZON-ERCID: 101096705
EC Contribution
€24,827
Consortium Size
1 orgs
Start Year
2023
Summary

Fibrosis is a pathological feature caused by excessive extracellular matrix secretion, resulting in scar tissue that causes thickening and loss of tissue mobility, culminating in impaired organ function. It is a common feature of heart failure and non-alcoholic steatohepatitis and an important determinant of morbidity and mortality. However, relatively little is known about the underlying aetiology. We and others have mapped alterations in the gut microbiota in different cardiometabolic diseases, focusing on the functions performed by the microbiota. IMPACT builds on our work showing that humans with type 2 diabetes have high plasma levels of the microbial metabolite imidazole propionate (ImP) and that ImP impairs insulin signalling through p38gamma. We also resolved the X-ray crystal structure of urocanate reductase (UrdA), the bacterial enzyme responsible for ImP production. Our recent work showed that ImP is more strongly associated with heart failure and that treatment of mice with ImP promotes both cardiac and liver fibrosis, consistent with studies showing that p38gamma signalling is implicated in fibrosis development.IMPACT will first use state-of-the-art clinical assessments to determine how circulating levels of ImP correlate with fibrosis in heart and liver. Second, we will explore the kinetics by which ImP induces fibrosis in mice and how this process is associated with immune cell infiltration and disease progression. Third, to provide mechanistic understanding, we will perform similar experiments in mice lacking key target signalling components (e.g., p38gamma), combined with single cell sequencing that will guide us in producing tissue-specific knockouts to elucidate the cellular cross-talk. Fourth, we will generate UrdA inhibitors and test their potential to reduce ImP production in isolated bacteria, complex microbial communities, and colonised mice. Thus, IMPACT has the potential of generating new therapies to diseases with unmet clinical needs.

Consortium (1)

Project Results (5)

Source: CORDIS, the EU research results database.

Publications (4)
Gut microbiota-derived imidazole propionate predicts cardiometabolic risk in patients with coronary artery disease
European Heart Journal· 2025DOI
Florian A Wenzl, Peizhi Wang, Florian Kahles, Katharina R Beck, Evangelos Giannitsis, Slayman Obeid, Francesco Bruno, Xinmin S Li, David Nanchen, Luca Liberale, Maria A Smolle, Victor Schweiger, Roland Klingenberg, Robert Manka, Barbara E Stähli, Christian Templin, Maximilian König, Jinqing Yuan, Mustafa Yildirim, Michael Lehrke, Arnold von Eckardstein, Nikolaus Marx, François Mach, Lorenz Räber, Hugo A Katus, Elisabeth Steinhagen-Thiessen, Ilja Demuth, John Deanfield, Peter Libby, Stanley L Hazen, Arash Haghikia, Ulf Landmesser, Fredrik Bäckhed, Thomas F Lüscher
Imidazole propionate is a driver and therapeutic target in atherosclerosis
Nature· 2025DOI
Annalaura Mastrangelo; Iñaki Robles-Vera; Diego Mañanes; Miguel Galán; Marcos Femenía-Muiña; Ana Redondo-Urzainqui; Rafael Barrero-Rodríguez; Eleftheria Papaioannou; Joaquín Amores-Iniesta; Ana Devesa; Manuel Lobo-González; Alba Carreras; Katharina R. Beck; Sophie Ivarsson; Anders Gummesson; Georgios Georgiopoulos; Manuel Rodrigo-Tapias; Sarai Martínez-Cano; Ivan Fernández-López; Vanessa Nuñez; Alessia Ferrarini; Naohiro Inohara; Kimon Stamatelopoulos; Alberto Benguría; Danay Cibrian; Francisco Sánchez-Madrid; Vanesa Alonso-Herranz; Ana Dopazo; Coral Barbas; Jesús Vázquez; Juan Antonio López; Alicia González-Martín; Gabriel Nuñez; Konstantinos Stellos; Göran Bergström; Fredrik Bäckhed; Valentín Fuster; Borja Ibañez; David Sancho
Microbiome–metabolome dynamics associated with impaired glucose control and responses to lifestyle changes
Nature Medicine· 2025DOI
Hao Wu; Bomin Lv; Luqian Zhi; Yikai Shao; Xinyan Liu; Matthias Mitteregger; Rima Chakaroun; Valentina Tremaroli; Stanley L. Hazen; Ru Wang; Göran Bergström; Fredrik Bäckhed
Molecular Metabolism
Molecular Metabolism· 2025DOI
Mattias Bergentall; Valentina Tremaroli; Chuqing Sun; Marcus Henricsson; Muhammad Tanweer Khan; Louise Mannerås Holm; Lisa Olsson; Per-Olof Bergh; Antonio Molinaro; Adil Mardinoglu; Robert Caesar; Max Nieuwdorp; Fredrik Bäckhed
Deliverables (1)
Data Management Plan